Received Feb 16, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 1 | — | OT |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 2 | — | OT |
No symptoms reported/No additional AE; her son received his first dose of MMR II under the age of 1 year; This spontaneous report was received from a pharmacist who was also the patient's parent and referred to a 8 months male patient. The patient's pertinent medical history, concurrent conditions, drug reactions or allergies, and concomitant therapies were not reported. On 08-May-2019, under the age of 1 year due to travelling internationally, the patient was vaccinated with the first dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) (dose, route of administration, anatomical site, lot# and expiration date not reported); the vaccine was reconstituted with sterile diluent (MERCK STERILE DILUENT) (lot# and expiration date not reported) as prophylaxis (Product administered to patient of inappropriate age). Afterwards, on 16-Sep-2019, the patient was vaccinated with the second dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) (dose, route of administration, anatomical site, lot# and expiration date not reported); the vaccine was reconstituted with sterile diluent (MERCK STERILE DILUENT) (lot# and expiration date not reported) as prophylaxis. No symptoms reported, no additional adverse event (No adverse event). Batch/Lot number is being requested and will be submitted if received.
MERCK STERILE DILUENT